118 related articles for article (PubMed ID: 22704161)
1. Neoadjuvant chemotherapy with HER2 inhibitors for breast cancer.
Brede-Hekimian K
Lancet; 2012 Jun; 379(9833):2237; author reply 2238. PubMed ID: 22704161
[No Abstract] [Full Text] [Related]
2. Neoadjuvant chemotherapy with HER2 inhibitors for breast cancer.
Fujita T
Lancet; 2012 Jun; 379(9833):2237; author reply 2238. PubMed ID: 22704160
[No Abstract] [Full Text] [Related]
3. RE: Comparative effectiveness of neoadjuvant therapy for HER2-positive breast cancer: a network meta-analysis.
Qi X; Ji LJ; Zhang X; Ma Y; Ma W
J Natl Cancer Inst; 2015 Apr; 107(4):. PubMed ID: 25739417
[No Abstract] [Full Text] [Related]
4. Making sense of dual HER2-targeting in early breast cancer?
Carey LA; Barry W
J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25224563
[No Abstract] [Full Text] [Related]
5. Dual inhibition of HER2 in breast cancer treatment.
Gnant M; Steger GG
Lancet; 2012 Feb; 379(9816):596-8. PubMed ID: 22257672
[No Abstract] [Full Text] [Related]
6. Response.
Nagayama A; Hayashida T; Jinno H; Takahashi M; Kitagawa Y
J Natl Cancer Inst; 2015 Apr; 107(4):. PubMed ID: 25739418
[No Abstract] [Full Text] [Related]
7. Dual HER2 targeting for early breast cancer.
Johnston SR
Lancet Oncol; 2013 Nov; 14(12):1145-6. PubMed ID: 24095298
[No Abstract] [Full Text] [Related]
8. Comparative effectiveness of neoadjuvant therapy for HER2-positive breast cancer: a network meta-analysis.
Nagayama A; Hayashida T; Jinno H; Takahashi M; Seki T; Matsumoto A; Murata T; Ashrafian H; Athanasiou T; Okabayashi K; Kitagawa Y
J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25224562
[TBL] [Abstract][Full Text] [Related]
9. Targeted treatments for breast cancer: a step forward.
Bachelot T; Tredan O
Lancet Oncol; 2013 May; 14(6):438-9. PubMed ID: 23602602
[No Abstract] [Full Text] [Related]
10. Better treatments needed for breast cancer brain metastases.
Lin NU
Lancet Oncol; 2015 Dec; 16(16):1583-4. PubMed ID: 26596673
[No Abstract] [Full Text] [Related]
11. Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer.
Guarneri V; Dieci MV; Frassoldati A; Maiorana A; Ficarra G; Bettelli S; Tagliafico E; Bicciato S; Generali DG; Cagossi K; Bisagni G; Sarti S; Musolino A; Ellis C; Crescenzo R; Conte P
Oncologist; 2015 Sep; 20(9):1001-10. PubMed ID: 26245675
[TBL] [Abstract][Full Text] [Related]
12. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
Robidoux A; Tang G; Rastogi P; Geyer CE; Azar CA; Atkins JN; Fehrenbacher L; Bear HD; Baez-Diaz L; Sarwar S; Margolese RG; Farrar WB; Brufsky AM; Shibata HR; Bandos H; Paik S; Costantino JP; Swain SM; Mamounas EP; Wolmark N
Lancet Oncol; 2013 Nov; 14(12):1183-92. PubMed ID: 24095300
[TBL] [Abstract][Full Text] [Related]
13. The Dual Role of Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Two Sides of the Same Coin?
Loibl S
JAMA Oncol; 2015 Jul; 1(4):455-6. PubMed ID: 26181253
[No Abstract] [Full Text] [Related]
14. Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial.
Cortés J; Dieras V; Ro J; Barriere J; Bachelot T; Hurvitz S; Le Rhun E; Espié M; Kim SB; Schneeweiss A; Sohn JH; Nabholtz JM; Kellokumpu-Lehtinen PL; Taguchi J; Piacentini F; Ciruelos E; Bono P; Ould-Kaci M; Roux F; Joensuu H
Lancet Oncol; 2015 Dec; 16(16):1700-10. PubMed ID: 26596672
[TBL] [Abstract][Full Text] [Related]
15. COUNTERPOINT: HER2-Targeted Combinations in Advanced HER2-Positive Breast Cancer.
Pegram MD
Oncology (Williston Park); 2015 Nov; 29(11):797, 801-2. PubMed ID: 26573059
[No Abstract] [Full Text] [Related]
16. Estimated Life-Years Saved in Women with HER2-Positive Metastatic Breast Cancer Receiving First-Line Trastuzumab and Pertuzumab in the United States.
Danese MD; Masaquel A; Santos E; Brammer M; Lee A; Lalla D
Value Health; 2015 Sep; 18(6):876-83. PubMed ID: 26409616
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
Gianni L; Pienkowski T; Im YH; Roman L; Tseng LM; Liu MC; Lluch A; Staroslawska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi G; Szado T; Ratnayake J; Ross G; Valagussa P
Lancet Oncol; 2012 Jan; 13(1):25-32. PubMed ID: 22153890
[TBL] [Abstract][Full Text] [Related]
18. POINT: HER2-Targeted Combinations in Advanced HER2-Positive Breast Cancer.
Goel S; Winer EP
Oncology (Williston Park); 2015 Nov; 29(11):797-8, 802. PubMed ID: 26573058
[No Abstract] [Full Text] [Related]
19. Treatment combinations for HER2-positive breast cancer.
Pegram M
Oncology (Williston Park); 2013 Apr; 27(4):258, 260. PubMed ID: 23781688
[No Abstract] [Full Text] [Related]
20. Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial.
Wu W; Deng H; Rao N; You N; Yang Y; Cao M; Liu J
Trials; 2017 Oct; 18(1):497. PubMed ID: 29070044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
